{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:08:48Z","timestamp":1788851328900,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jhep.2021.09.013","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T15:20:04Z","timestamp":1632756004000},"page":"302-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR"],"prefix":"10.1016","volume":"76","author":[{"given":"Roberta","family":"D\u2019Ambrosio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4669","authenticated-orcid":false,"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-5575","authenticated-orcid":false,"given":"Maria Paola","family":"Anolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8295-0098","authenticated-orcid":false,"given":"Ilaria","family":"Fanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Soffredini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-6504","authenticated-orcid":false,"given":"Massimo","family":"Iavarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-9575","authenticated-orcid":false,"given":"Giulia","family":"Tosetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-1256","authenticated-orcid":false,"given":"Riccardo","family":"Perbellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-9385","authenticated-orcid":false,"given":"Angelo","family":"Sangiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-7614","authenticated-orcid":false,"given":"Vana","family":"Sypsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.09.013_bib1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.21176","article-title":"The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients","volume":"43","author":"Sangiovanni","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.013_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A\u00a0sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib3","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2021.09.013_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.013_bib5","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/liv.13707","article-title":"Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression","volume":"38","author":"D\u2019Ambrosio","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.09.013_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"Van der Meer","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.013_bib8","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2017.03.017","article-title":"Direct-acting antivirals: the endgame for hepatitis C?","volume":"24","author":"D'Ambrosio","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhep.2021.09.013_bib10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.09.013_bib11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct-acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib12","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep.29097","article-title":"Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the heap-C registry","volume":"65","author":"Fernandez Carrillo","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.013_bib13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.013_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.013_bib15","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.013_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors associated with increate risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib19","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.013_bib20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virological response to Interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2020.02.022","article-title":"Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: an ERCHIVES study","volume":"73","author":"Butt","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/hep.1840200104","article-title":"Intraobserver and inter-observer variations in liver biopsy in liver biopsy interpretation in patients with chronic hepatitis C","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.013_bib26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/gut.2006.111302","article-title":"Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease","volume":"56","author":"Fraquelli","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.09.013_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib28","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension. Report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib31","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter north American cohort study","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.013_bib32","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib33","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on ELTR registry","volume":"69","author":"Belli","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib34","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/liv.13878","article-title":"Delisting HCV-infected liver transplant candidates who improve after viral eradication: outcome 2 years after delisting","volume":"38","author":"Perricone","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.09.013_bib35","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Ripoll","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib36","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2020.05.042","article-title":"Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance","volume":"73","author":"Mak","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.013_bib38","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jvh.13232","article-title":"Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis","volume":"27","author":"McDonald","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.09.013_bib39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2018.11.022","article-title":"Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events","volume":"156","author":"Butt","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.013_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ahj.2017.10.024","article-title":"Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients","volume":"198","author":"Cacoub","year":"2018","journal-title":"Am Heart J"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821020432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821020432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:53Z","timestamp":1759175033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821020432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0168827821020432"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.09.013","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740901628.793590432","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}